Drug Discovery Featured Articles & Applications
The Global Landscape For Synthetic Biology In Biopharma Through 2035
Synthetic biology — redesigning the genetic material of organisms — offers a lot of potential with processes like protein engineering and genetic engineering. Using new market research, let's look at emerging trends, market opportunities, regional analysis, and other notable insights.
Tapping Into AI/ML Partnerships To Advance Drug Discovery With Recursion Pharma
"TechBio" company Recursion Pharma has entered agreements to acquire AI/ML company Cyclica for $40 million and Valence for $47.5 million. To learn about the acquisitions and the future of AI/ML in drug discovery and development, we caught up with Recursion’s CEO Chris Gibson.
Targeting Von Willebrand Factor With An RNA Aptamer To Treat Stroke
Developing new treatments for acute ischemic stroke that can quickly and safely intervene at the right place and time has been a challenging endeavor. Today, the situation is changing due to technological developments related to stroke and recent advances in RNA-based medicines.
Perfused Organ Models: An Alternative To Animal Testing
Animal testing has been a long-standing practice in biomedical research, providing valuable insights into disease mechanisms, drug efficacy, and safety. However, ethical concerns, limitations of animal models, and increasing awareness of animal welfare have prompted the development of alternative methods — like perfused organ models (POMs).
Should My Biotech Startup Buy Or Produce The Proteins We Use?
"Should we build out an internal group of scientific expertise or delegate work to external vendors?," is a question that this author has faced in his career. He shares key considerations building protein science teams.
How Predictive Can Regulatory Drug Abuse Potential Investigations Be in Animals?
Is addiction attributed to “the animal or the human within us” or is substance abuse unique to humans? This question has intrigued me since the EMA guidance on Non-clinical Investigation of the Dependence Potential of Medicinal Products in 2006 and the FDA guidance on Assessment of Abuse Potential of Drugs in 2010 have requested the performance of dedicated studies in animals. Let's take a closer look at the matter.
The Global Market For AI In Drug Discovery To Sextuple By 2027
The integration of artificial intelligence (AI) in drug discovery has been a game-changer, significantly improving efficiency and accuracy, and its use is growing exponentially. This article shares market drivers, market restraints, and emerging trends.
The 2 Factors Driving A Surge In Aptamer Use In Drug Discovery
Aptamers offer advantages over antibodies, including lower immunogenicity and toxicity, better tissue penetration, lower production costs, and a very long shelf life. Why, then, have we not seen more of these come to market? Two hurdles have stood in the way until recently.
FDA Adopts ICH Guidance On Assessing Nonclinical Biodistribution Of Gene Therapy Viral Vectors
An important step in the gene therapy development process is assembling biodistribution data in suitable animals in relation to the intended clinical population. Developing an accurate biodistribution profile is influenced by factors such as the route of administration, dose level(s), dosing regimen, and the animal immune response to the gene therapy product. The FDA adopted this ICH guidance in May 2023, and the EMA plans to adopt it in September 2023.
Optimizing Digitalization To Accelerate Your R&D
Drug/therapy development has made significant leaps in innovation in recent years, but common issues that hinder progress still exist. Are you harnessing and optimizing your data for speedier drug development and quicker launch timescales? This article shares important recommendations.